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ess: l.koenderman@umSummary Chronic inflammation of the airways is a hallmark of chronic obstructive
pulmonary disease (COPD). We investigated the kinetics of priming of inflammatory
cells in peripheral blood during exacerbations of COPD and during the resolution
phase.
Modulation of the leukocyte compartment as a consequence of systemic
activation by cytokines/chemokines was determined by measuring the expression
of priming-associated epitopes by novel antibodies designated A17 and A27.
Furthermore, H2O2 was determined in breath condensate as a read out for local
inflammation. Leukocytes were obtained from COPD patients (GOLD II–IV) during and
after an exacerbation of their disease.
During an exacerbation the expression of priming epitopes on leukocytes was
increased. This priming phenotype disappeared upon treatment with intravenous
corticosteroids. Similarly, H2O2 levels in breath condensate were also increased
during an exacerbation and decreased upon treatment.
We conclude that the activation status of neutrophils in the systemic
compartment can be used as a read-out for systemic innate immune signals involved
in the pathogenesis of COPD. The correlation between H2O2 in exhaled air with A27
priming on neutrophils showed that local inflammation has systemic effects on cells
of the innate immune system.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is
defined as a disease state characterized by an
irreversible, usually progressive airflow limitation.1
Central in the pathogenesis of COPD is the
inflammatory reaction found in the airways and
the alveolar structures, which leads to persistent
injury.2 The clinical course of COPD is often
accompanied by recurrent exacerbations, which
contribute to a more rapid decline in lung function
and health status.3,4 Most prominent in the disease
process is the ongoing inflammation with an
increase of neutrophils, monocytes and T lympho-
cytes in the lung parenchyma.5,6
An increase of cytokines and chemokines is often
observed in sputum and bronchoalvolar lavage
studies of COPD patients which are clear indicators
for the inflammatory process.6,7 These cytokines/
chemokines are involved in modulation of leuko-
cytes responses in vivo. The unique mix of pro-and
anti-inflammatory mediators will determine
whether leukocytes are preactivated (primed) or
inhibited functionally.5 Preactivation or priming is a
prerequisite for homing to and optimal activation
of granulocytes in the tissues and can be monitored
by recently developed phage antibodies A17 and
A27.8 Despite the fact that these antibodies
recognize epitopes highly expressed on primed
myeloid leukocytes the identity of these priming
structures remains to be elucidated. A systemic
increase in pro-inflammatory cytokines and chemo-
kines as well as an increased expression of their
receptors on the leukocytes are likely to lead to an
increased number of systemically primed neutro-
phils.9,10 This will facilitate the margination,
extravasation and accumulation of inflammatory
cells into the tissues.
Therefore, only ‘partially’ primed cells can be
found in the peripheral compartment.8 Leukocytes
obtained from bronchoalveolar lavage (BAL) fluid
have an increased expression of priming markers
compared to the expression in the peripheral
blood.8 Insight into the mechanisms of priming of
peripheral blood leukocytes of patients with COPD
will contribute to the understanding of the kinetics
of the systemic inflammatory processes, which are
associated with the disease. In addition, priming of
leukocytes can be used as read-out for the in vivo
action of pro- and anti-inflammatory cytokines.
We performed a study regarding the priming
status of neutrophils during an exacerbation of
COPD and during resolution of this clinical condi-
tion. To determine whether inflammation-asso-
ciated priming of neutrophils in the peripheral
blood was accompanied by a change in a tissueassociated inflammatory marker, H2O2 in breath
condensate was measured. We will show that
systemic neutrophil preactivation is increased
during an exacerbation of COPD and that local
inflammation is inducing an activation of the
systemic innate immune system.Materials, methods and patients
Reagents
Recombinant human GM-CSF was from Genzyme
(Boston, MA, USA). Human serum albumin (HSA)
was obtained from the Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service
(Amsterdam, The Netherlands). RPMI 1640 medium
with Glutamax was purchased from Life Technolo-
gies (Breda, The Netherlands). Ficoll-Paque was
from Pharmacia (Uppsala, Sweden).
Study population and design
Ten patients with unstable moderate to very severe
COPD were selected from our outpatient clinic
population (Department of Pulmonary Diseases,
Heart & Lung Center Utrecht, St. Antonius Hospital
Nieuwegein) when they suffered from a severe
exacerbation requiring hospitalization.11 The pa-
tients had to have a smoking history of at least 10
pack years and they fulfilled the criteria for the
diagnosis of moderate to very severe COPD accord-
ing to the GOLD guidelines.1,12 At the time of
hospitalization they suffered from two or all three
of the following symptoms: an increase from
baseline of sputum production, sputum purulence
or shortness of breath, and they were unresponsive
to outpatient therapy.13 The exacerbations were
not life-threatening and did not need intensive care
unit management. Patients were allowed to use
glucocorticosteroids (GCS) and bronchodilators at
admission. Patients with uncontrolled severe dis-
eases other than COPD contributing to the dete-
rioration were excluded. At inclusion before the
start of treatment, at the third or fourth day and at
day 7 of the treatment period a lung function was
performed, the Borg score was reported by the
patient (0 ¼ no dyspnea to 10 ¼ maximum dys-
pnea),14 exhaled breath condensate was collected
and blood samples were drawn. The subjects were
treated according to the ERS guidelines on COPD.15
In short, GCS (Di-Adreson-F aquosum) was adminis-
tered intravenously, 50mg 24 h1 which was ta-
pered to 25mg 24 h1 after 3–4 days. Oxygen given
through a nasal canula was titrated to reach a PaO2
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hypercapnia. Physiotherapy was applied to improve
clearance of secretions and to control breathing
patterns. Current smokers refrained from smoking
during admission. All subjects gave written in-
formed consent to be included in the study, which
was approved by the local Ethics Committee.
Procedure for staining phagocytes with FITC-
labeled MoPhabs A17, A27 and other
activation markers
Two human monoclonal phage antibodies were
isolated from a synthetic bacteriophage antibody
library. These phage antibodies recognize epitopes
that are upregulated on neutrophils, eosinophils
and monocytes in whole blood, and these epitopes
are expressed on the cells at low priming concen-
trations of cytokines such as GM-CSF and TNFa.16
Peripheral leukocytes of normal donors do not
exhibit a primed phenotype.8,16 An increase in
expression of priming-associated cellular markers
will be shortly named priming. Blood was collected
from COPD patients and normal control and put on
ice immediately after venapuncture and kept at
4 1C. A volume of 100 ml of FITC-labeled MoPhab
(A17 and A27) was added to 50 ml of whole blood
before lysis of the red cells to minimize artificial
activation by ex vivo manipulation of the samples.
After incubation for 90min on ice, red cells were
lysed in ice-cold NH4Cl. Hereafter, the cells were
washed and taken up in PBS/1%HSA.16,17
For the measurement of expression of CD18
(DAKOcytomation, Gostrup, Denmark), CD63
(Ancell, Bayport, USA), CD62L (BD Pharmingen,
Franklin Lakes, USA) and CD11b (DAKOcytomation,
Gostrup, Denmark) cells were lysed after stimula-
tion and incubated directly with FITC or PE-labeled
antibody (1:100). An isotype control, FITC or PE-
conjugated antibody was used. After incubation
cells were washed and taken up in PBS/1%HSA.
Cells were analyzed in a FACS vantage flowcyt-
ometer (Becton & Dickinson, Mountain View, CA,
USA). The different phagocytes were identified
according to their specific side-scatter and for-
ward-scatter signals.18–20
Measurement of H2O2 in exhaled air
condensate
Exhaled air condensate was sampled in the morning
after measurement of the lung function according
the guidelines of ATS/ERS Task Force21 as described
before22 In short, before collection a mouth wash
was performed using 15ml chlorohexidine (0.2%)during 1min to eliminate contamination of expired
breath with mouth flora. The exhaled breath
condensate samples were taken between 8.30 and
9.30 a.m. The patients were spontaneously breath-
ing through a mask with a two-way valve (Downs
CPAP Mask, Vital Signs Inc., USA) for a 20min
period. The expired breath condensate was col-
lected by passing the exhaled air through a
specially constructed collecting device which con-
sisted of a 140 cm cold finger with an internal
diameter of 15mm. At the end of the colfd finger,
the condensate was collected into small glass
container. This device was placed in a polystyrene
foam container filled with ice, water and salt (2
to 5 1C). A second collecting device was coupled
to the first device to be sure that all the exhaled
breath did indeed condensate. After the collection
the condensate was immediately transported to the
laboratory in a light protected vial and stored at
70 1C and processed within 7 days. The amount of
H2O2 in the condensate was detected by a method
described previously.22 Briefly, H2O2 causes the
oxidation of the substrate 3,30,5,50-tetramethyl-
benzidine, a process that is catalyzed by horse-
radish peroxidase. The reaction product was
measured using a spectrophotometer at 450 nm
using an automated microplate reader. The absor-
bency recorded is directly proportional to the
concentration of H2O2.
Data analysis
Data are presented as means7standard error of the
mean (SEM). Statistical analysis was performed with
repeated measurement ANOVA, using the Student’s
t-test for paired observations when appropriate.
Correlation coefficients were calculated by using
Pearson’s method.Results
Characteristics of the patient population
with COPD
Ten COPD patients with a severe, non-life-threa-
tening exacerbation were included.11 In the days
prior to admission, all subjects developed a
deterioration of their lung disease. The most
important clinical features at the time of admission
are presented in Table 1. Mean age of the patients
was 64.672.4 yr (male/female: 6/4). Patients had
a mean FEV1 of 38% of predicted at admission (see
Fig. 3B), whereas they had a mean FEV1 of 54% of
predicted (range 35–69%) under stable conditions.
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radiological signs of pneumonia were present in any
of the patients. Hospital management included
standard treatment with bronchodilator nebulisa-
tion, oxygen administration and physiotherapy,
along with systemic theophylline and high-dose
GCS. Antibiotics were prescribed when patients
with worsening dyspnea and cough also had
increased sputum purulence1,13 and were adjusted
when appropriate. All patients completed the study
and could be discharged after 13.671.4 days.
Comparison of different activation epitopes
on granulocytes-induced activation of whole
blood with GM-CSF
Whole blood was stimulated for 15min with GM-
CSF. After stimulation expression of several priming
markers was measured by flow cytometry (seeTable 1 Patient characteristics at inclusion.
Sex, male/female (n/n) (6/4)
Age, yr 64.672.4
Pack-years smoking 28.973.6
FEV1, l 1.1070.17
FEV1, % predicted 37.874.5
FVC, l 2.5870.38
FVC, % predicted 66.977.9
moPhage A17 (AU) neutrophils 52.6714.0
moPhage A27 (AU) neutrophils 265.3734.1
H2O2, nmol l
1 452.5733.9
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Figure 1 GM-CSF (1–0.001 nM)-induced expression of priming
FITC-labeled MoPhaps A17 and A27 is shown in panel (A) and
expression of activation epitopes recognized CD11b, CD18, CD
1 nM GM-CSF are shown. The antibodies were directly labele
shown as the mean-fold increase of the GM-CSF stimulate
bars7SEM, n ¼ 7, Po0:05).materials and methods). In Fig. 1A the fold increase
in expression of priming epitope A17 on GM-CSF
stimulated neutrophils is compared to non-stimu-
lated neutrophils. Stimulation with GM-CSF 109
and 1010 M significantly increased the expression
of priming epitope (Po0:05). The expression of A27
is significantly induced by GM-CSF stimulation in
the concentration range 109, 1010 and 1011 M
(Po0:05). In panel C, the expression of different
priming markers on neutrophils stimulated with
GM-CSF 109 M are compared and shown in Fig. 1.Modulation of systemic neutrophil
compartment in COPD
Patients who where admitted to the hospital with
an exacerbation of COPD showed an increase in the
expression of moPhab A17 and A27 on peripheral
blood neutrophils (A17 52.6714.0 vs. A27
265.3734.1) (Fig. 2A and B). No subpopulations
of neutrophils with discrete expression patterns
were found. After 3 days of treatment of the
exacerbation the priming of neutrophils was de-
creased. At 7 days of treatment the priming of A17
was decreased to 20.274.2 AU (Po0:005), and the
expression of A27 was decreased to 102.4734.9 AU
(Po0:05). Tapering of the systemic GCS after 3 days
of treatment did not induce a rebound effect on the
expression of moPhab A17 or A27 expression on
neutrophils.fo
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epitopes on neutrophils of normal donors recognized by
(B), respectively. In panel (C), a comparative analysis of
62L and CD 63 antibodies on neutrophils stimulated with
d with FITC or PE. The expression of priming markers is
d sample compared to the unstimulated sample (error
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The H2O2 samples of exhaled air displayed a high
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Figure 2 The effect of 1-week treatment of patients with an
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Figure 3 The effect of 1-week treatment of patients with
function (FEV1) and (C) (Borg) dyspnea score. Data are showing increased oxidative stress in the airways at
admission (Fig. 3A). By the time of discharge, the
exhaled H2O2 content had fallen from 452.5733.9
to 236.3727.0 nmol l1, i.e. 35.776.3% of theadmission day 3-4 day 7
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significant change in the lung function (FEV1)
was observed during the first week of treatment
(Fig. 3B). On the contrary, the perception of
dyspnea, determined by each patient with the help
of the Borg dyspnea scale decreased significantly
during treatment (Po0:05) (Fig. 3C).
A moderate but significant correlation was
found between H2O2 values and the expression of
the priming epitope A27 on circulating neutro-
phils (r ¼ 0:41, Po0:05) (Fig. 4A). A17 was not0 100 200 300 400 500
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Figure 4 Correlations between markers of systemic inflamma
in exhaled air, a marker for local inflammation correlates wit
(A) and not with moPhab A17 (B). In addition, the Borg score
with moPhab A27 expression on peripheral blood neutrophils (
individual subject during the study period and fluorescence
coefficients (Pearson) and P values are shown in each figure.significantly related with H2O2 (r ¼ 0:04, P ¼ 0:83)
(Fig. 4B). In addition, the Borg score correlated with
the H2O2 (r ¼ 0:5, Po0:01, Fig. 4C) as well as with
the A27 expression (r ¼ 0:65, Po0:0001, Fig. 4D).Discussion
The present study was undertaken to investigate
aspects of systemic inflammation in COPD patientsH
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D). Every point represents the values corresponding to an
is expressed as median fluorescent intensity. Correlation
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following recovery phase in a unique context.
Analysis of modulation of the leukocyte compart-
ment in peripheral blood by determination of
priming epitope expression on peripheral leuko-
cytes is an elegant method to study the kinetics of
systemic innate immune responses.8,16 Previously,
we showed that the local inflammatory response in
COPD patients is reflected by a systemic activation
of leukocytes.16 In another study, we demonstrated
a changed gene expression profile of pro- and anti-
inflammatory genes in peripheral blood neutrophils
obtained from patients with COPD.23 Expression of
CD83, MIP-1a, IL-1RA, IL-1b, IL1-R2 in peripheral
neutrophils correlated with the severity of COPD as
measured by FEV1.
23 This observation confirms the
hypothesis that the inflammatory process in COPD is
not restricted to the lungs but communicates with
the systemic immune response.
The concept of enhanced homing of primed
neutrophils to the tissues is corroborated by recent
findings. Ariga et al. demonstrated an increased
neutrophil recruitment in the lungs of mice
challenged with LPS.24 In vitro, an increase in
adhesion receptor expression and chemotaxis was
observed after stimulation with inflammatory med-
iators like TNFa and fMLP.25 Furthermore, neutro-
phils isolated from COPD patients with a fast
decline in lung function were shown to express
higher levels of the integrin Mac-1.26,27 In addition,
previous experiments showed that the expression
of priming epitopes is markedly increased on
eosinophils obtained from the BAL fluid of allergic
patients locally challenged with allergen.8 There-
fore, we hypothesized that the increase in periph-
eral primed neutrophils observed during an
exacerbation of COPD16 should be normalized upon
optimal treatment.
To compare and validate our method of priming
of systemic neutrophils we compared the expres-
sion of several well-known priming/activation
markers such as a subunit of MAC-1 (CD11b), b
subunit of MAC-1 (CD18), L-selectin (CD62L) and
azurophil granula marker (CD63) with our newly
developed priming markers, A17 and A27. The
markers we used in this study for the measurement
of the expression of priming epitopes on leukocytes
were more sensitive to priming stimuli compared to
the other markers (see Fig. 1 and Luijk et al.8 and
Koenderman et al.16). Therefore we used the
markers A17 and A27 to investigate the priming/
activation status of neutrophils in this study.
Increased expression of priming-associated mar-
kers on neutrophils was observed during a severe
exacerbation of COPD. Already after 3–4 days of
treatment of the exacerbation the expression ofpriming epitopes on the neutrophils was normal-
izing (see Fig. 2). In addition to the measurement of
priming, we determined the concentration of H2O2
in exhaled air to investigate if the local inflamma-
tion was related to the systemic inflammation
(Fig. 3). Previously it was shown by Dekhuijzen et
al. that the concentration of H2O2 in expired air
was increased during an exacerbation of COPD.28
We show that upon treatment the increased H2O2
levels decreased, indicating that the inflammation
due to the exacerbation was decreasing.29 The lung
function as measured by FEV1 did not respond on
treatment in contrast to the inflammation markers
and the dyspnea score.14 This discrepancy suggests
that the lung function is a weak tool for monitoring
an exacerbation of COPD.
The increase in expression of priming epitopes on
peripheral blood neutrophils during an exacerba-
tion of COPD can be explained by an increase in the
local inflammatory processes. In a simular study
performed by Gerritsen et al.22 the serum concen-
trations of IL-8, ICAM-1 and E-selectin were
measured. During treatment of the exacerbation
the concentrations of IL-8 and ICAM-1 declined
significantly.22 This is in line with our observation
that the priming of neutrophils decreased upon
treatment.
These data are consistent with studies that show
an aggravated inflammatory process in COPD during
an exacerbation of the disease and an increase in
the number of neutrophils and lymphocytes in the
sputum or BAL fluid.30–33 Interestingly, high base-
line levels of IL-6 and IL-8 in the sputum showed
that patients had a higher exacerbation frequency,
indicating that an activated inflammatory process
is related to recurrent exacerbations.34 The local
increase of inflammation in the lungs results in an
increased production of inflammatory mediators
and low doses of peripheral cytokines/chemokines
are already capable of priming the leukocytes.16
Therefore the increase of primed granulocytes in
the peripheral blood in patients with COPD can be
associated with a worsening of their clinical
condition due to an activation of the inflammatory
process.
The concentration of H2O2 in exhaled air can be
used as a marker for local inflammation, because
an increase in the number and activation of
inflammatory cells in the lungs will be reflected
by an increase in H2O2 production.
35 This has been
shown in several studies, e.g. patients with com-
munity acquired pneumonia had elevated levels of
H2O2 in their exhaled air condensate.
30 In addition,
a significant correlation was observed between
serum CRP concentration and the concentration of
H2O2 in exhaled air.
36 The results of this latter study
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blood neutrophil A27 expression and H2O2 concen-
tration in exhaled air were correlated. To our
surprise, systemic inflammation reflected in prim-
ing of peripheral blood neutrophils as well as local
inflammation as determined by an increase in H2O2
concentration was correlated with the patients’
sensation of dyspnea (Borg score). This observation
indicates that the systemic immune response, the
local inflammation and patients well being are in
close relation with each other. Unexpected was the
lack of a correlation between FEV1 and Borg score,
the patients sensation of dyspnea is not related to
this lung function. Apparently, the sensation of
dyspnea not only dependent on FEV1 but probably
also related with general well being.
In conclusion, primed neutrophils can be found in
peripheral blood during an exacerbation of COPD.
Upon treatment of the exacerbation the priming of
neutrophils as well as the H2O2 concentration
decreased. The activation status of peripheral
blood neutrophils correlated with H2O2 in the
breath condensate. These observations showed
that the expression of priming-associated markers
in peripheral neutrophils can be used as read out
for the inflammatory processes in COPD.References
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